The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression : 96-week analysis results of the MODAT study / V. Spagnuolo, L. Galli, A. Bigoloni, S. Nozza, A.D. Monforte, A. Antinori, A. Di Biagio, S. Rusconi, G. Guaraldi, S. Di Giambenedetto, A. Lazzarin, A. Castagna. - In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. - ISSN 1758-2652. - 17:4, suppl. 3(2014 Nov 02), pp. 19806.190-19806.191. ((Intervento presentato al convegno International Congress of Drug Therapy in HIV Infection tenutosi a Glasgow (UK) nel 2014 [10.7448/IAS.17.4.19806].
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression : 96-week analysis results of the MODAT study
S. Rusconi;
2014
Abstract
The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
rusconi_19806-14877-1-PB.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
228.53 kB
Formato
Adobe PDF
|
228.53 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
